LumiraDx's SARS-CoV-2 RNA STAR Assay Secures FDA Emergency Use Authorization
By LabMedica International staff writers Posted on 14 Aug 2020 |
Illustration
LumiraDx (London, UK) has secured Emergency Use Authorization from the US Food and Drug Administration (FDA) for its SARS-CoV-2 RNA STAR assay.
The LumiraDx SARS-CoV-2 RNA STAR is a molecular test kit which uses a non-isothermal nucleic acid amplification qSTAR (Selective Temperature Amplification Reaction) method intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens (such as nasal, mid-turbinate, nasopharyngeal and oropharyngeal swabs) and bronchoalveolar lavage specimens collected from individuals suspected of COVID-19 by their healthcare provider.
It is used for the qualitative detection of RNA from SARS-CoV-2 (COVID-19). The patient sample is collected and purified through standard automated or manual extraction processes. The sample is then added to the MasterMix where it is transcribed to cDNA. If the virus is present in the sample, it will be amplified by the qSTAR technology in approximately 12 minutes. Following the rapid amplification of the virus, the target is specifically detected with molecular beacons to which the results are reported out as positive or negative.
Nucleic acid extraction is performed using Qiagen's QIAsymphony DSP Virus/Pathogen Kit and automated QIAsymphony SP instrument or manually using either Thermo Fisher's MagMax Viral/Pathogen Nucleic Acid Isolation Kit or Qiagen's QIAamp Viral RNA Mini Kit. The test can run on a variety of instruments including Roche's LightCycler 480 II, Thermo Fisher's Applied Biosystems 7500 Fast Dx and QuantStudio 5, and Agilent's AriaMx and Stratagene Mx3005P. The LumiraDx SARS-CoV-2 RNA STAR assay has been validated from common upper respiratory tract specimens in Universal Transport Medium.
Related Links:
LumiraDx
The LumiraDx SARS-CoV-2 RNA STAR is a molecular test kit which uses a non-isothermal nucleic acid amplification qSTAR (Selective Temperature Amplification Reaction) method intended for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens (such as nasal, mid-turbinate, nasopharyngeal and oropharyngeal swabs) and bronchoalveolar lavage specimens collected from individuals suspected of COVID-19 by their healthcare provider.
It is used for the qualitative detection of RNA from SARS-CoV-2 (COVID-19). The patient sample is collected and purified through standard automated or manual extraction processes. The sample is then added to the MasterMix where it is transcribed to cDNA. If the virus is present in the sample, it will be amplified by the qSTAR technology in approximately 12 minutes. Following the rapid amplification of the virus, the target is specifically detected with molecular beacons to which the results are reported out as positive or negative.
Nucleic acid extraction is performed using Qiagen's QIAsymphony DSP Virus/Pathogen Kit and automated QIAsymphony SP instrument or manually using either Thermo Fisher's MagMax Viral/Pathogen Nucleic Acid Isolation Kit or Qiagen's QIAamp Viral RNA Mini Kit. The test can run on a variety of instruments including Roche's LightCycler 480 II, Thermo Fisher's Applied Biosystems 7500 Fast Dx and QuantStudio 5, and Agilent's AriaMx and Stratagene Mx3005P. The LumiraDx SARS-CoV-2 RNA STAR assay has been validated from common upper respiratory tract specimens in Universal Transport Medium.
Related Links:
LumiraDx
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants